Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityNo recent work listed

Georgios Gemenetzis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0549-1369; OpenAlex author ID A5071876295. Sources: OpenAlex.

Their work

Papers
22 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
93
Papers, trials and grants by year

2018: 6 papers · 2019: 5 papers · 2020: none · 2021: 3 papers · 2022: 5 papers · 2023: 3 papers

Papers 22

  1. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  2. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  3. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal … Co-author DOI 10.1097/sla.0000000000005710↗
  4. Robotic versus open pancreaticoduodenectomy with vascular resection for pancreatic ductal adenocarcinoma: surgical and oncological outcomes from pilot experien… Co-author DOI 10.1007/s00423-021-02364-w↗
  5. Oncological outcomes of robotic pancreatectomy in patients with pancreatic cancer who receive adjuvant chemotherapy: A propensity score-matched retrospective c… Co-author DOI 10.1016/j.ijsu.2022.106801↗
  6. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.sopen.2022.07.007↗
  7. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  8. The Role of Diffusion-Weighted Magnetic Resonance Imaging in Staging After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma: Reply. First author DOI 10.1245/s10434-022-11737-4↗
  9. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  10. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. Co-author DOI 10.1097/sla.0000000000003568↗
  11. Surgical Management of Non-Metastatic Pancreatic Cancer in the United Kingdom: Results of a Nationwide Survey on Current Practice. Co-author DOI 10.3389/fonc.2021.791946↗
  12. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.04.007↗
  13. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. Co-author DOI 10.1016/j.hpb.2018.12.002↗
  14. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/sla.0000000000002734↗
  15. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Co-author DOI 10.1097/sla.0000000000002753↗
  16. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-0197↗
  17. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25288↗
  18. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2017.12.021↗
  19. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conven… Co-author DOI 10.1016/j.surg.2017.11.027↗
  20. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? Co-author DOI 10.1097/sla.0000000000002672↗
  21. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study. Co-author DOI 10.1097/sla.0000000000002925↗
  22. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-018-6558-7↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Peng He · 16 shared papers, 2018–2022 · strength 1.56
  2. Alex B. Blair · 14 shared papers, 2018–2022 · strength 1.42
  3. Vincent P. Groot · 15 shared papers, 2018–2023 · strength 1.37
  4. Matthew John Weiss · 15 shared papers, 2018–2022 · strength 1.30
  5. Christopher Lee Wolfgang · 14 shared papers, 2018–2022 · strength 1.22
  6. Richard Andrew Burkhart · 11 shared papers, 2018–2023 · strength 0.97
  7. Ding Ding · 9 shared papers, 2018–2023 · strength 0.81
  8. Ammar A. Javed · 8 shared papers, 2018–2023 · strength 0.71
  9. Jun Yu · 8 shared papers, 2018–2021 · strength 0.62
  10. Ralph H. Hruban MD · 7 shared papers, 2018–2022 · strength 0.56
  11. Elliot K. Fishman · 6 shared papers, 2018–2022 · strength 0.49
  12. Lei Zheng · 6 shared papers, 2018–2022 · strength 0.49
  13. Daniel A. Laheru · 5 shared papers, 2018–2022 · strength 0.41
  14. Izaak Quintus Molenaar · 5 shared papers, 2018–2019 · strength 0.39
  15. William R. Burns · 3 shared papers, 2021–2023 · strength 0.35
  16. Amol Kumar Narang · 4 shared papers, 2019–2022 · strength 0.35
  17. Chenghong Peng · 2 shared papers, 2022 · strength 0.31
  18. Xiaxing Deng · 2 shared papers, 2022 · strength 0.31
  19. Yuanchi Weng · 2 shared papers, 2022 · strength 0.31
  20. Jiabin Jin · 2 shared papers, 2022 · strength 0.31
  21. Kelly J. Lafaro · 2 shared papers, 2022–2023 · strength 0.27
  22. Joseph M. Herman · 3 shared papers, 2018–2022 · strength 0.26
  23. Nigel Balfour Jamieson · 2 shared papers, 2021–2023 · strength 0.26
  24. Bradley Norman Reames · 2 shared papers, 2021–2022 · strength 0.25
  25. Chandrakanth Are · 2 shared papers, 2021–2022 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.